InsiderTrades

Form 4 for QNRX Quoin Pharmaceuticals Ltd.

Accepted 2025-10-15 00:00:00 ET · period of report 2025-10-14 · accession 0001104659-25-099782 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-10-15 2025-10-14 QNRX LANGER DENNIS Dir P - Purchase $8.49 +15.2K 15.2K +1,515,200% +$128.6K
DM 2025-10-15 2025-10-14 QNRX LANGER DENNIS Dir P - Purchase — +60.6K 15.2K New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common ADSs 2025-10-14 P A 15,152 $8.49 15,153 D — — (F1) Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
2 Derivative Series H Warrants (Right to Buy) 2025-10-14 P A 15,152 — 15,152 D $9.08 · 2025-10-14 to — 15,152 ADS (F2) Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants." (F3) The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap. (F4) The Series H Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the Company's public announcement that the Company has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome.
3 Derivative Series I Warrants (Right to Buy) 2025-10-14 P A 15,152 — 15,152 D $10.31 · 2025-10-14 to — 15,152 ADS (F2) Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants." (F3) The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap. (F5) The Series I Warrants will expire as follows: (i) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the monotherapy pivotal trial of QRX003 for the treatment of Netherton Syndrome, and (ii) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the adjuvant pivotal trial of QRX003 for the treatment of Netherton Syndrome.
4 Derivative Series J Warrants (Right to Buy) 2025-10-14 P A 15,152 — 15,152 D $12.38 · 2025-10-14 to — 15,152 ADS (F2) Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants." (F3) The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap. (F6) The Series J Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome.
5 Derivative Series K Warrants (Right to Buy) 2025-10-14 P A 15,152 — 15,152 D $12.38 · 2025-10-14 to — 15,152 ADS (F2) Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants." (F3) The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap. (F7) The Series K Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the Company's sale of a Priority Review Voucher (PRV).